MARKET

GKOS

GKOS

Glaukos Corp
NYSE
108.68
-0.21
-0.19%
Opening 13:56 05/28 EDT
OPEN
109.32
PREV CLOSE
108.89
HIGH
109.32
LOW
107.43
VOLUME
88.21K
TURNOVER
0
52 WEEK HIGH
113.97
52 WEEK LOW
45.38
MARKET CAP
5.47B
P/E (TTM)
-37.7204
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Perspective Therapeutics (CATX) and Glaukos (GKOS)
TipRanks · 6h ago
Weekly Report: what happened at GKOS last week (0520-0524)?
Weekly Report · 1d ago
Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns
Simply Wall St · 4d ago
Glaukos Price Target Raised to $130.00/Share From $120.00 by Citigroup
Dow Jones · 6d ago
Glaukos Is Maintained at Buy by Citigroup
Dow Jones · 6d ago
Glaukos (GKOS) Receives a Buy from Piper Sandler
TipRanks · 05/21 11:35
Weekly Report: what happened at GKOS last week (0513-0517)?
Weekly Report · 05/20 09:22
Glaukos (GKOS) Reaches 52-Week High: What's Aiding the Stock?
NASDAQ · 05/14 16:20
More
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Webull offers Glaukos Corp stock information, including NYSE: GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.